The company’s new advancements could lead to new product introductions and revenue in areas not contemplated by us previously, thus enhancing the value that much more.

With a great deal of experience in protocol design, Nuvilex management is well on its way to designing, compiling, and completing the necessary steps in order to move forward as quickly as possible.

The Company released news that should have been received by investors as its most significant event to date, excluding the acquisition of rights to the ground-breaking live-cell encapsulation technology to treat cancer. Instead, it was treated as a ho-hum event. Here’s why investors that missed the significance will be caught napping.

With October (The Breast Cancer Awareness Month) around the corner, it is interesting to note that Plandaí¬ Biotechnology, Inc.’s (OTCQB – PLPL - $0.55 – Spec Buy) Phytofare™ Citrus Products may prove to be useful in the fight against breast cancer due to the high bioavailability of its citrus bioflavonoid product.

Global Payout, Inc. is at the apex of the huge global electronic payments and prepaid card industry.

These events bode very well for LifeApps Digital Media, Inc. (OTCQB – LFAP - $0.076 – Spec Buy) and other mobile media players as a rising tide lifts all boats.

There is a buzz in certain biotech circles regarding the high value of encapsulation technologies and targeted therapy delivery platforms. For example, Bind Therapeutics, Inc., a high profile biotech that recently filed to go public via an Initial Public Offering through leading health care investment banks, is one of these companies. Considering the striking similarities between Bind and Nuvilex, Inc. (OTCQB – NVLX - $0.15 – Spec Buy), Nuvilex’s shares could enjoy a big boost once Bind’s IPO registration becomes effective.

One of the key catalysts in the near term for Nuvilex Inc. (OTCQB – NVLX - $0.146 – Spec Buy) is the establishment of a GMP (Good Manufacturing Practices) facility. The facility will be used to encapsulate the live cells that are part of the Company’s pancreatic cancer treatment necessary for future clinical trials.